Abstracts Archive - Page 277 of 2607 - ACR Meeting Abstracts

Abstract Number: 0657 • ACR Convergence 2024
Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis
Jagan K L¹, Augustine Jose², Vishnupriya G¹, Dellan S¹, Dhanush S¹, Samskruthi Reddy Tokala¹, Bhavana Mashetty¹, Chengappa Kavadichanda³, Sachith ganapathy¹, Aishwarya Gopal⁴, Rithik Roshan¹, Sareddy Sai vignesh Reddy¹, Sonal Mehra⁵, Molly Thabah¹ and Vir Singh Negi⁶, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ²Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁵JAYPEE HOSPITAL, Noida, Uttar Pradesh, India, ⁶AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), with 14-33% failing to respond to standard treatments. This study assesses treatment…
Abstract Number: 0629 • ACR Convergence 2024
Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus
Anca Askanase¹, Edward Vital², Oliver Meier³, Armando Turchetta⁴, Huiyan (Ashley) Mao⁴, Justine Maller⁵, Jorge A. Ross Terres⁶ and Maria Dall'Era⁷, ¹Columbia University Medical Center, New York, NY, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc,, San Francisco, CA, ⁶Genentech, Inc,, San Francisco, ⁷UCSF, Corte Madera, CA
Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…
Abstract Number: 0628 • ACR Convergence 2024
Genetic Determinants of Childhood Onset Systemic Lupus Erythematosus
Meghan Nelson¹, Shanta Murthy², Sushma Maddipatla², Sreekala Shenoy², Lori Ponder³, Subra Kugathasan⁴, Dave Cutler⁵ and Sampath Prahalad⁶, ¹Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America; Children’s Healthcare of Atlanta, Atlanta, United States of America; National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland; Department of Human Genetics; Emory University School of Medicine, Atlanta, Georgia, United States of America, Bethesda, MD, ²Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America; Children’s Healthcare of Atlanta, Atlanta, United States of America, Atlanta, GA, ⁵Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States of America, Atlanta, GA, ⁶Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a multisystem autoimmune disease with significant morbidity and mortality. Genome-wide association studies have identified more than 100 variants…
Abstract Number: 0660 • ACR Convergence 2024
Hydroxychloroquine Users at Lower Risk of Kidney Function Decline in Lupus Nephritis
Shivani Garg¹, Brad Rovin², Brad Astor¹, Tripti Singh¹, Lexie Kolton¹, Callie Saric¹, S. Sam Lim³ and Christie Bartels⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²The Ohio State University, Columbus, OH, ³Emory University, Atlanta, GA, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone in treatment of systemic lupus erythematosus (SLE), yet its role in preventing kidney function decline in lupus nephritis (LN)…
Abstract Number: 0641 • ACR Convergence 2024
Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Katherine Chakrabarti¹, Apurba Chakrabarti², Emily Lewis² and William McCune³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Hospital, Ann Arbor, MI, ³U Michigan, Ann Arbor, MI
Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…
Abstract Number: 0566 • ACR Convergence 2024
How Early Is Early? Unveiling Time to Diagnosis Since Symptom Onset and Its Determinants in Patients Suspected of Early Axial Spondyloarthritis: Data from the SPondyloArthritis Caught Early (SPACE) Cohort
Mary Lucy Marques¹, Desiree van der Heijde², Liese de Bruin³, Miranda van Lunteren⁴, Robert Landewé⁵, Karen Minde Fagerli⁶, Maikel Van Oosterhout⁷, Floris van Gaalen⁸ and Sofia Ramiro⁹, ¹Leiden University Medical Center, Coimbra, Zuid-Holland, Portugal, ²Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ⁵Amsterdam University Medical Center, Meerssen, Netherlands, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Groene Hart Ziekenhuis, Gouda, the Netherlands, Gouda, Netherlands, ⁸LUMC, Leiden, Zuid-Holland, Netherlands, ⁹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Patients with chronic back pain (CBP) of less than two-years (2y) duration suspected of axial spondyloarthritis (axSpA) referred to the rheumatologist can be reliably…
Abstract Number: 0669 • ACR Convergence 2024
Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study
buddhika Jayaratna¹, Pasan Serasinghe², Louise Nel³, Sahil Jain³, Shrish Sangle², Begona Lopez¹, Giovanni Sanna², Michelle Fernando¹ and David DCruz⁴, ¹Guys & St Thomas NHS Foundation Trust, London, United Kingdom, ²Guys & St Thomas NHS Foundation Trust, London, England, United Kingdom, ³Guys and St Thomas' Hospital, London, United Kingdom, ⁴The Louise Coote Lupus Unit, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multi-system autoimmune rheumatic disorder. Despite therapeutic advances, managing SLE remains challenging due to its complex pathogenesis and…
Abstract Number: 0562 • ACR Convergence 2024
Serum Interleukin IL-40 as a Potential Biomarker Associated with Pro-inflammatory Activity in Inflammatory Bowel Diseases and Spondyloarthritis: A Preliminary Study
Lucia Ondrejčáková¹, Adéla Navrátilová², Monika Gregová³, Kristýna Bubová⁴, Tomáš Grega⁵, Ladislav Šenolt⁶, Karel Pavelka⁷ and Lucie Andrés Cerezo⁸, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, ²1st Faculty of Medicine, Charles University and Institute of Rheumatology in Prague, Hlavní mesto Praha, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology and Charles University, Prague, Czech Republic, ⁵3Department of Internal Medicine, First Faculty of Medicine, Charles University, Military University Hospital, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Interleukin 40 (IL-40) is a novel cytokine with a proposed role in the pathogenesis of inflammatory diseases. Inflammatory bowel diseases (IBD)-associated with spondyloarthritis (SpA)…
Abstract Number: 0567 • ACR Convergence 2024
Alteration of JAK-STAT Signaling in an Axial Spondyloarthritispatient with TYK2 Variants
Pankaj Sharma¹, Fatemeh Navid¹, Norman Watts¹, Stephen Brooks² and Robert Colbert², ¹National Institutes of Health, Bethesda, MD, ²NIH/NIAMS, Bethesda, MD
Background/Purpose: Tyrosine kinase 2 (TYK2) is a member of the Janus kinase family that associates with the cytoplasmic domain of type I/II cytokine receptors and…
Abstract Number: 0656 • ACR Convergence 2024
Lupus Myocarditis: Clinical Characteristics, Cardiac Magnetic Resonance Imaging Findings and Outcomes
María del Carmen Zamora-Medina¹, Erik Cimé-Aké², Emilio G. Lazarini², Wallace Rafael A. Muñoz-Castañeda³ and Hilda Fragoso-Loyo², ¹Instituto Nacional de Perinatología "Isidro Espinoza de los Reyes". Rheumatology Department, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Hospital Medica Sur. Rheumatology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: Limited information about lupus myocarditis (LM) comes from small case series. The aim of our study is to describe and compare clinical characteristics, cardiac…
Abstract Number: 0671 • ACR Convergence 2024
Effect of Litifilimab on Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) Subcomponents and Physician Global Assessment–Skin (PGA–Skin) in Patients with Cutaneous Lupus Erythematosus (CLE) in a Phase 2 Study
Victoria Werth¹, Joseph F. Merola², Qianyun Li³, Weihong Yang³ and Catherine Barbey⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²UT Southwestern Medical Center, Dallas, TX, ³Biogen, Cambridge, MA, ⁴Biogen, Baar, Switzerland
Background/Purpose: In the randomized, placebo-controlled Phase 2 LILAC study of litifilimab (NCT02847598), Part B (participants with active CLE with/without SLE) met its primary endpoint of…
Abstract Number: 0652 • ACR Convergence 2024
Analysis of Relapses in a Single Center Cohort of Patients with Lupus Nephritis
Gamze Kemec¹, Sibel Varelci², Erdem Gurel², Isın Kılıcaslan³, Yasemın özlük³, Yasemın Yalcınkaya⁴, Ahmet Gul⁵, Murat Inanc⁶ and bahar Artım Esen⁴, ¹Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine Istanbul Faculty of Medicine, Istanbul, Turkey, ³Department of Pathology Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Division of Rheumatology, Department of Internal Medicine, Istanbul, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, ⁶Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Relapses are correlated with increased hospitalizations, poor renal outcomes, morbidity and mortality. We aim to investigate the incidence, predictive factors and outcomes related to…
Abstract Number: 0603 • ACR Convergence 2024
Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
Jakub Závada¹, Jana Baranová², Karel Pavelka¹, Jiří Vencovský³, Pavel Horak⁴, Kateřina Kusalová² and Ladislav Šenolt³, and collaborators of the ATTRA registry, ¹Institute of Rheumatology and Charles University, Praha, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic
Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
Abstract Number: 0610 • ACR Convergence 2024
Clinical Evaluation on IFI44L Gene Methylation Detection for Diagnosis of Systemic Lupus Erythematosus by Methylation Sensitive High Resolution Melting (MS-HRM)
Xiaoping hong and liancheng lin, The Second Clinical Medical College of Jinan University, Shenzhen, China (People's Republic)
Background/Purpose: To evaluate the clinical effectiveness of IFI44L gene methylation detection for the diagnosis of Systemic Lupus Erythematosus (SLE) by MS-HRM, to determine the relative…
Abstract Number: 0604 • ACR Convergence 2024
Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024
Mahum Mirza¹, Jean Liew², Michael Putman³ and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Treatment options for psoriasis or psoriatic arthritis (PsA) have expanded in the past decade. Secular trends in biologic disease modifying antirheumatic drug (bDMARD) prescribing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].